Pentwater Capital Management LP said it trimmed its economic stake in Ondine Biomedical Inc to 3.001803% from 4.053088%, according to a filing on the London Stock Exchange’s Regulatory News Service.
The investment firm, controlled by Matthew Halbower and based in Naples, held 16,846,666 shares on a synthetic basis through cash-settled swap agreements. Pentwater reported no direct ownership of Ondine Biomedical shares, with its entire position maintained via derivative instruments.
The reduction crossed the 3% threshold on September 1, with the company notified the following day. The disclosure was published on September 3 at 05:00 AM, based on the Regulatory News Service filing.
